BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician’s Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI. J of Skin [Internet]. 2020 Sep. 2 [cited 2025 May 18];4(5):s29. Available from: https://skin.dermsquared.com/skin/article/view/978